Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,226 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,226 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00422877 | Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary… | Phase 2 | terminated | Jan 17, 2007 | American Regent, Inc. | Sponsor suspended development of the drug on September 3, 2008. | Other (stated, no rule matched) |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | Phase 2 | terminated | Aug 8, 2019 | NYU Langone Health | Study was terminated early by the drug sponsor due to slow accrual and a change in the company's… | Enrollment / accrual |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT06275854 | YASU Research Registry: For Young Adults With Cancer | — | terminated | Feb 23, 2024 | Young Adult Survivors United | Sponsoring organization no longer desired to recruit/maintain registry | Enrollment / accrual |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3… | Early Phase 1 | terminated | Jan 15, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04363801 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With…(DisTinGuish) | Phase 2 | terminated | Apr 27, 2020 | Leap Therapeutics, Inc. | experimental treatment will not be more efficacious than its comparator in the primary endpoint of… | Other (stated, no rule matched) |
| NCT06730100 | CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable… | Phase 2 | withdrawn | Dec 12, 2024 | National Cancer Institute (NCI) | no accruals | Enrollment / accrual |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT02982694 | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant,… | Phase 2 | terminated | Dec 5, 2016 | Vall d'Hebron Institute of Oncology | The results of the interim analysis showed that the efficacy in the MSS subgroup (MSI like) is… | Efficacy / futility |
| NCT03417921 | A Study of ABTL0812 in Pancreatic Cancer(Pancreatic) | Phase 1 / Phase 2 | suspended | Jan 31, 2018 | Ability Pharmaceuticals SL | We opened another study. | Other (stated, no rule matched) |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected… | Phase 1 | terminated | Jun 27, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04827732 | Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in…(IMPARC) | N/A | terminated | Apr 1, 2021 | Washington University School of Medicine | Slow enrollment | Enrollment / accrual |
| NCT05350501 | EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual…(CLAUDE) | Phase 2 | terminated | Apr 28, 2022 | Enterome | the study recruitment is significantly behind expectations as only one single patient has started… | Enrollment / accrual |
| NCT04693546 | Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test…(PREVENT) | — | suspended | Jan 5, 2021 | Metabiomics Corp | fundraising | Other (stated, no rule matched) |
| NCT05221320 | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced… | Phase 2 | terminated | Feb 2, 2022 | BioMed Valley Discoveries, Inc | Lack of Enrollment for Remaining Open Baskets | Enrollment / accrual |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Phase 1 | terminated | Feb 21, 2024 | Ikena Oncology | Limited resources and strategic priorities | Sponsor / business decision |
| NCT06302400 | Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable…(RHEPaiR) | N/A | terminated | Mar 8, 2024 | Imperial College London | Terumo Europe NV permanently discontinued production of Holmium platform SIRT product range | Other (stated, no rule matched) |
| NCT04938973 | NIF-Guided RAMIE Using ICG Versus OTE Feasibility RCT(RAMIE vs OTE) | N/A | terminated | Jun 25, 2021 | St. Joseph's Healthcare Hamilton | The study was closed due to adverse events because the adverse event rate was not lower than the… | Safety / toxicity |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab… | Phase 1 / Phase 2 | terminated | Feb 20, 2020 | Bolt Biotherapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT05013554 | Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory… | Phase 1 | terminated | Aug 19, 2021 | Sanofi | not stated | Not stated |
| NCT05582018 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of…(PANORAMA) | N/A | terminated | Oct 17, 2022 | Techsomed Medical Technologies LTD | Sponsor decision | Sponsor / business decision |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | Phase 2 | terminated | Jan 10, 2023 | NuCana plc | A pre-planned initial analysis concluded that the study was unlikely to achieve its primary… | Other (stated, no rule matched) |
| NCT06410534 | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint… | Phase 2 | withdrawn | May 13, 2024 | National Cancer Institute (NCI) | PI left NIH. | Investigator |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H… | Phase 2 | withdrawn | Nov 15, 2024 | National Cancer Institute (NCI) | PI left NIH. | Investigator |
| NCT04502082 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) | Phase 1 | terminated | Aug 6, 2020 | Eureka Therapeutics Inc. | The trial was intended to be a Phase 1/2 trial, but the sponsor terminated the trial prior to… | Other (stated, no rule matched) |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | Phase 2 | withdrawn | Oct 16, 2023 | Institut Bergonié | Discontinuation of molecule development | Other (stated, no rule matched) |
| NCT00766142 | Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis…(COCHISE) | Phase 2 | terminated | Oct 3, 2008 | Institut Bergonié | In 2008, new data highlighted that Cetuximab had no efficacy in case of KRAS mutation. As such,… | Efficacy / futility |
| NCT03765736 | Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal… | — | terminated | Dec 5, 2018 | Academic and Community Cancer Research United | Low accrual | Enrollment / accrual |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | Phase 2 | terminated | Aug 18, 2021 | National Cancer Institute (NCI) | Reason for termination was a combination of slow accrual in setting of austerity measures regarding… | Enrollment / accrual |
| NCT06217016 | Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer… | N/A | withdrawn | Jan 22, 2024 | The First Hospital of Jilin University | The ICCAUT-1 trial failed to demonstrate the superiority of the ICCAUT strategy in urinary… | Sponsor / business decision |
| NCT05451862 | Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular…(HOMIE-166) | N/A | terminated | Jul 11, 2022 | Terumo Europe N.V. | The HOMIE-166 clinical investigation was prematurely terminated due to sponsor's decision to… | Sponsor / business decision |
| NCT06420908 | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal… | N/A | withdrawn | May 20, 2024 | Hebei Medical University Fourth Hospital | The primary reason for termination was difficulty in recruitment | Enrollment / accrual |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Phase 1 | terminated | Nov 4, 2022 | 3B Pharmaceuticals GmbH | Sponsor reprioritization of active trials. | Other (stated, no rule matched) |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | terminated | May 27, 2016 | Eli Lilly and Company | The study was terminated due to business considerations | Sponsor / business decision |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and… | Phase 1 | terminated | Aug 14, 2025 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04057365 | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With… | Phase 2 | terminated | Aug 15, 2019 | Massachusetts General Hospital | Based on a Simon 2-stage design, this study did not meet response criteria to proceed to stage 2. | Other (stated, no rule matched) |
| NCT05975645 | A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib… | Phase 1 | terminated | Aug 4, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT05743036 | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | Phase 1 | terminated | Feb 24, 2023 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Study terminated due to change in therapeutic landscape. | Other (stated, no rule matched) |
| NCT04141995 | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | Phase 2 | terminated | Oct 28, 2019 | University of Nebraska | Due to low accrual and futility | Efficacy / futility |
| NCT03320629 | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic… | Phase 2 | terminated | Oct 25, 2017 | Hebei Medical University Fourth Hospital | This study was voluntarily terminated after investigator assessment, with no safety concerns… | Safety / toxicity |
| NCT04645797 | A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With… | Phase 1 | terminated | Nov 27, 2020 | Apros Therapeutics, Inc | Study terminated prematurely due to internal corporate decision | Other (stated, no rule matched) |
| NCT05591534 | Endorectal Brachytherapy for Rectal Cancer(ICUREC) | Phase 2 | suspended | Oct 24, 2022 | University Hospital, Bordeaux | Unknown time frame for availability of new endorectal probes | Other (stated, no rule matched) |
| NCT02070705 | DCE MRI in Patients With Pancreatic Cancer | N/A | terminated | Feb 25, 2014 | OHSU Knight Cancer Institute | Loss of funding | Funding |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T… | — | terminated | Nov 18, 2021 | Alaunos Therapeutics | TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business… | Sponsor / business decision |
| NCT05678205 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With… | Phase 1 / Phase 2 | withdrawn | Jan 10, 2023 | Artiva Biotherapeutics, Inc. | Corporate business decision | Sponsor / business decision |
| NCT05917990 | Dyadic Text-Messaging Micro-Intervention | N/A | withdrawn | Jun 26, 2023 | Duke University | PI accepted a faculty position at a different institution, and the postdoctoral grant was terminated | Other (stated, no rule matched) |
| NCT03316872 | Study of Pembrolizumab and Radiotherapy in Liver Cancer | Phase 2 | terminated | Oct 20, 2017 | University Health Network, Toronto | The study was stopped due to the shift in systemic treatment paradigm for HCC precluding further… | Enrollment / accrual |
| NCT05634525 | Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant… | Phase 1 | withdrawn | Dec 2, 2022 | M.D. Anderson Cancer Center | No participants enrolled | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 16, 2025source: clinicaltrials